Business, energy, technology, markets and global industry news from Business News Today

neovascular age-related macular degeneration

PharmaDeviceNews neovascular age-related macular degeneration
A retinal specialist reviews advanced eye scans as Memento Medicines develops MMT-205 to challenge established treatments for wet age-related macular degeneration and diabetic macular edema. Representative image.
Pharma & Biotech

Memento Medicines launches with $93m, but can MMT-205 challenge retinal drug leaders?

Discover how Memento Medicines plans to challenge retinal drug leaders with $93 million, MMT-205 and a direct Tie2 activation strategy.

Read More
Representative image of retinal injection research and ophthalmology diagnostics used to illustrate Innovent Biologics’ Phase 3 efdamrofusp alfa breakthrough in neovascular age-related macular degeneration treatment.
Pharma & Biotech

Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data

Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.

Read More